ImmuCell Corporation (ICCC)
Stock Price:
$5.77 USD
-0.23 (-3.85%)
Updated December 3, 2:00 PM EST - Market open
Key Info
| Market Cap |
41.61M |
| Revenue (ttm) |
15.23M |
| Net Income (ttm) |
-1.52M |
| Shares Out |
7.21M |
| EPS (ttm) |
-0.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 3 |
| Last Price |
$5.77 |
| Previous Close |
$6.00 |
| Change ($) |
-0.23 |
| Change (%) |
-3.85% |
| Day's Open |
5.99 |
| Day's Range |
5.74 - 5.89 |
| Day's Volume |
6,210 |
| 52-Week Range |
3.79 - 6.35 |
More Stats
| Market Cap |
41.61M |
| Enterprise Value |
45.27M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
7.21M |
| Float |
n/a |
| EPS (basic) |
-0.21 |
| EPS (diluted) |
-0.21 |
| FCF / Share |
-0.44 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3,588 |
| Short Ratio |
0.33 |
| Short % of Float |
n/a |
| Beta |
1.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.73 |
| PB Ratio |
1.50 |
| Revenue |
15.23M |
| Operating Income |
-988,455 |
| Net Income |
-1.52M |
| Free Cash Flow |
-3.17M |
| Net Cash |
-3.66M |
| Net Cash / Share |
-0.51 |
| Gross Margin |
44.25% |
| Operating Margin |
-6.49% |
| Profit Margin |
-10.00% |
| FCF Margin |
-20.79% |
| ROA |
-1.57% |
| ROE |
-5.32% |
| ROIC |
-3.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
14.0
Current: $5.77
High
14.0
Target: 14.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 13.72 | 10.99 | 10.43 | 9.54 | 10.23 | 7.60 | 6.01 | 5.39 | 5.11 | 4.39 |
| Revenue Growth | 24.91% | 5.32% | 9.3% | -6.69% | 34.64% | 26.46% | 11.45% | 5.45% | 16.53% | - |
| Gross Profit | 6.74 | 5.19 | 5.22 | 5.42 | 6.25 | 4.45 | 3.06 | 3.05 | 2.81 | 2.30 |
| Operating Income | -0.95 | -1.45 | -0.24 | 0.89 | 2.12 | -0.21 | -0.02 | 0.25 | -0.63 | -0.69 |
| Net Income | -1.30 | -2.32 | -0.17 | 0.51 | 1.21 | -0.17 | 0.12 | 0.09 | -0.41 | -0.38 |
| Shares Outstanding | 6.82 | 5.49 | 4.95 | 4.23 | 3.04 | 3.03 | 3.02 | 3.02 | 2.98 | 2.97 |
| Earnings Per Share | -0.19 | -0.42 | -0.03 | 0.12 | 0.38 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 |
| EPS Growth | - | - | - | -68.42% | - | - | 33.33% | - | - | - |
| Operating Cash Flow | 0.23 | -0.37 | 1.18 | -0.22 | 2.90 | 0.30 | 1.10 | 0.34 | -0.04 | -0.81 |
| Capital Expenditures | -0.94 | -1.78 | -17.71 | -3.56 | -2.65 | -1.54 | -0.60 | -0.28 | -0.24 | -0.12 |
| Free Cash Flow | -0.71 | -2.15 | -16.54 | -3.78 | 0.25 | -1.23 | 0.50 | 0.07 | -0.28 | -0.93 |
| Cash & Equivalents | 8.77 | 2.52 | 3.80 | 10.62 | 6.04 | 3.34 | 5.26 | 4.91 | 4.96 | 4.63 |
| Total Debt | 8.42 | 9.77 | 8.96 | 3.01 | 3.19 | 0.90 | 1.09 | 1.27 | 1.44 | 0.99 |
| Net Cash / Debt | 0.35 | -7.24 | -5.16 | 7.61 | 2.86 | 2.44 | 4.17 | 3.65 | 3.52 | 3.64 |
| Assets | 38.69 | 32.73 | 34.30 | 24.70 | 14.54 | 11.05 | 10.96 | 11.03 | 10.99 | 10.75 |
| Liabilities | 9.70 | 10.99 | 10.70 | 4.98 | 3.93 | 1.79 | 1.56 | 1.84 | 1.97 | 1.47 |
| Book Value | 28.99 | 21.74 | 23.59 | 19.72 | 10.61 | 9.26 | 9.40 | 9.19 | 9.02 | 9.28 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ImmuCell Corporation |
| Country |
United States |
| Employees |
53 |
| CEO |
Michael Brigham |
Stock Information
| Ticker Symbol |
ICCC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ICCC |
| IPO Date |
April 30, 1987 |
Description
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.